title: [Are therapeutic LDL goals justified? Controversies between the European and American guidelines].
abstract: Dyslipidemia is one of the most important risk factors of the cardiovascular disease, so its treatment is one of the key strategies of cardiovascular prevention. Statins have been consolidated as the reference treatment for the reduction of serum cholesterol levels. There are some divergences in the treatment of dyslipidemia between American and European guidelines. This narrative review discusses the key points of this controversy.
authors.affiliation: Servicio de Cardiología, Hospital Universitario de San Juan, San Juan de Alicante, España. Address: Carretera Nacional Km. 332, Alicante-Valencia s/n, San Juan de Alicante, España Email: vicentebertomeumartinez@gmail.com.
authors.forename: Vicente
authors.initials: V
authors.lastname: Bertomeu-Martínez
mesh_terms: D002318:Cardiovascular Diseases / Q000209:etiology / Q000517:prevention & control*; D008078:Cholesterol, LDL / Q000097:blood*; D050171:Dyslipidemias / Q000150:complications / Q000188:drug therapy*; D005060:Europe; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000008:administration & dosage; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D014481:United States
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors
keywords:  LDL cholesterol;  cardiovascular disease;  statins; dyslipidemia